Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-14T17:42:25.427Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidone for adolescent schizophrenia

Published online by Cambridge University Press:  02 January 2018

Ashok Kumar Jainer  and
Ahmad Mahmood
Ashok Kumar Jainer
Affiliation:
Coventry & Warwickshire Partnership Trust, Caludon Centre, Coventry CV2 2TE, UK. Email: ashokjainer@hotmail.com
Ahmad Mahmood
Affiliation:
St Michael's Hospital, Coventry & Warwickshire Partnership Trust, Coventry
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Information
The British Journal of Psychiatry , Volume 194 , Issue 6 , June 2009 , pp. 568 - 569
Copyright
Copyright © Royal College of Psychiatrists, 2009 

References

1 Haas, M, Eerdekens, M, Kushner, S, Singer, J, Augustyns, I, Quiroz, J, et al. Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009; 194: 158–64.Google Scholar
2 World Medical Association. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. WMA, 2008.Google Scholar
3 Hill, AB. Medical ethics and controlled trials. BMJ 1963; 1: 1043–9.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.